Walgreens Boots Alliance (NASDAQ:WBA) exceeded revenue expectations in the first quarter of CY2025, reporting a 4.1% increase in sales to $38.59 billion. The non-GAAP profit of $0.63 per share was 21% higher than what analysts had predicted.

Considering the recent performance, the question arises if this is an opportune time to invest in Walgreens. More insights can be found in our detailed research report.

Key highlights from Walgreens' Q1 CY2025 results include a revenue surpassing analyst estimates by 2.2%, reaching $38.59 billion, and an adjusted EPS of $0.63, beating analysts' predictions by 21%.

The pending acquisition by Sycamore Partners has led Walgreens to retract its fiscal 2025 guidance. The operating margin improved significantly to -14.4% from -35.5% in the same quarter of the previous year, while free cash flow stood at -$418 million, an improvement compared to -$989 million in the corresponding quarter last year. The company's market capitalization is currently at $9.26 billion.

Walgreens Boots Alliance, a pharmacy chain resulting from the merger of Walgreens and Alliance Boots in 2014, primarily offers prescription drugs, health, and beauty products.

The article also discusses general merchandise retailers, which provide a convenient one-stop shopping experience for customers, offering various products from clothing to home décor.

Examining Walgreens' sales growth over the last six years, it shows a moderate 2.9% compounded annual growth rate. While the company benefits from economies of scale, allowing it to offer competitive prices, expanding further might require adjustments in pricing strategies or venturing into new markets to drive sales growth.